A real-world comparative effectiveness analysis of macitentan versus ambrisentan and bosentan on hospitalizations and healthcare resource utilization in patients with pulmonary arterial hypertension

Pulmonary Hypertension

Clinical Characteristics and Treatment of Patients Diagnosed with Pulmonary Arterial Hypertension: A Real-World Study in the USA, Europe and Japan

Adv Ther

Vizza CD, Klok R, Harley J, Small M, Scott M, Lautsch D, White RJ

doi: 10.1007/s12325-024-03026-1

RECOMMENDED

Pulmonary Hypertension

Low nailfold capillary density in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: biomarker of clinical outcome?

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Sci Rep

Smits AJ, Isebia K, Combee-Duffy C, van der Wal S, Nossent EJ, Boonstra A, Vonk-Noordegraaf A, Bogaard HJ, Serné EH

doi: 10.1038/s41598-024-69017-y

COMMENTED

Pulmonary Hypertension

Effects of β-blockers on the Outcomes in Patients with Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: a Multicenter Prospective Cohort Study (BNP-PL)

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Waligóra M, Kurzyna M, Mularek-Kubzdela T, Skoczylas I, Chrzanowski Ł, Błaszczak P, Jaguszewski M, Kuśmierczyk B, Ptaszyńska K, Grześk G, Mizia-Stec K, Malinowska E, Peregud-Pogorzelska M, Lewicka E, Tomaszewski M, Jacheć W, Florczyk M, Mroczek E, Gąsior Z, Pawlak A, Betkier-Lipińska K, Pruszczyk P, Widejko K, Zabłocka W, Kopeć G

doi: 10.1016/j.chest.2024.10.051

Pulmonary Fibrosis

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Adv Ther

Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K, Ikeda R, Ochiai K, Sugiyama Y, Nukiwa T

doi: 10.1007/s12325-024-03079-2

RECOMMENDED

Asthma

Real-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Papaioannou O, Christopoulos I, Tsiri P, Sampsonas F, Karkoulias K, Lykouras D, Sotiropoulou V, Theohari E, Papalexatos D, Komninos D, Christopoulos A, Tzouvelekis A

doi: 10.3390/jcm14072174

Pulmonary Hypertension

Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials: a systematic review, meta-analysis and health-related quality of life framework

Eur Respir Rev

Varian F, Burney R, Pearson C, Goh ZM, Newman J, Rawlings G, Zafar H, Kiely DG, Thompson AAR, Condliffe R, Toshner M, McCormack C, Armstrong I, Peasgood T, Carlton J, Rothman AMK

doi: 10.1183/16000617.0006-2025

Pulmonary Hypertension

Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021

Lancet Respir Med

GBD 2021 Pulmonary Arterial Hypertension Collaborators

doi: 10.1016/S2213-2600(24)00295-9

Pulmonary Hypertension

Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model

Adv Ther

Alsumali A, McLaughlin V, Chevure J, Klok R, Zhang W, Martinez EC, Pausch C, De Oliveira Pena J, van de Wetering G, Jootun M, Lautsch D, Hoeper MM

doi: 10.1007/s12325-025-03241-4

RECOMMENDED

Pulmonary Hypertension

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Heart Lung Transplant

Rosenkranz S, Ghofrani HA, Hoeper MM, Langleben D, Hegab S, Rahner C, Richard JF, McLaughlin VV

doi: 10.1016/j.healun.2024.08.018

Related content

Clinical Characteristics and Treatment of Patients Diagnosed with Pulmonary Arterial Hypertension: A Real-World Study in the USA, Europe and Japan

Low nailfold capillary density in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: biomarker of clinical outcome?

Effects of β-blockers on the Outcomes in Patients with Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: a Multicenter Prospective Cohort Study (BNP-PL)

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan

Real-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry

Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials: a systematic review, meta-analysis and health-related quality of life framework

Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021

Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials